IgE-Selective Immunoadsorption for Eczema: Five Patients, 35 Procedures and an Uncontrolled Improvement Signal

November 9, 2026

Dr. Arsy #003 white 4 oz (120 g) jar in a new boxing-fitness scene; AI-created editorial illustration.

DOCTOR’S NOTES · ECZEMA EVIDENCE

Removing an immune protein from the circulation is a very different proposition from applying a moisturizer. A small IgE-selective immunoadsorption study reported meaningful changes in severe eczema, but its design cannot tell us how much improvement the procedure itself caused.

Who underwent the procedure?

The primary paper, published online in 2019 with a 2020 issue date, followed five adults with severe, difficult-to-control atopic dermatitis and elevated serum IgE. Three continued systemic immunosuppressive therapy. Each received seven individual treatments across three courses, totaling 35 procedures. The study was open-label and had no randomized control group.

Measurement	Reported result
Serum IgE	Mean reduction per course about 81%; this was not an 81% reduction in eczema severity.
Clinical response	SCORAD50 reached by 2/5; EASI50 by 3/5 at some point during the study.
Late follow-up	Week-29 analyses included four people after one withdrew for lack of response.
Safety observations	No adverse events reported in these five patients; rare risks cannot be quantified from this sample.

Thirty-five procedures were still five patients

Repeated sessions increase exposure information, but do not turn five people into 35 independent participants. The authors describe approximately three to four hours per session, with plasma separation and passage through an IgE-selective column before return to the patient. Their actual procedures used peripheral venous access. This is specialized clinical care, not a home blood-filtering or supplement approach.

The observed clinical changes were comparisons with each person’s own baseline. There was no sham-procedure arm to account for expectation, natural fluctuation or the contribution of continuing care. Three participants’ background systemic treatments make it particularly difficult to isolate the procedure’s added benefit.

The latest result came from fewer people

The participant who stopped during observation had not responded well. The last measurement was not carried forward into the week-29 analysis. Consequently, a later average from four remaining patients should not be presented as the outcome of all five originally enrolled. Attrition is part of the interpretation, not an administrative footnote.

The study also defined response at any measured time after the first course. A response achieved once during follow-up is not a guarantee of sustained control. Some patients rebounded, and an encouraging high-IgE subgroup was based on just three people.

What a specialist discussion needs

For a person managing employment, training and travel, visit burden matters alongside possible benefit. Ask why an invasive procedure is being considered, what alternative treatments are available, how response and recurrence would be measured, and what vascular-access, anticoagulation and monitoring requirements apply. Never suspend medicines to imitate a study protocol without the treating team’s instructions.

The result supports further research, not a routine recommendation for everyone with high IgE. Our photopheresis article reviews a different extracorporeal procedure; its evidence cannot be substituted for immunoadsorption.

Where daily moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in this research. These findings do not establish infant suitability or pediatric efficacy for #003. A child’s clinician can advise on appropriate moisture care.